More Post from the Author
- Global Military Products Awarded Contract Exceeding $635 Million for 155mm Artillery Munitions
- SJE Acquires AMI Global, Expanding Industrial Internet of Things (IIoT) Capabilities
- Lumenuity Selected as Finalist for Pepperdine's Most Fundable Companies of 2025
- APhA alarmed by claims of harm from acetaminophen without substantive science
- Exiger Named Presenting Sponsor Of Navy 250 Gala Celebrating Navy & Marine Corps' 250th Anniversary
Indivior Statement RE: Delayed FDA Approval of SUBLOCADE Label Changes
Published on Wed 12 Feb 2025 8:07:04 UTC
RICHMOND, Va., Feb. 12, 2025 /PRNewswire/ --Indivior PLC (Nasdaq/LSE: INDV)provides the following update regarding its PDUFA action date for label changes (rapid initiation protocol and alternative injection sites) for SUBLOCADE (buprenorphine extended-release) Injection, which was scheduled for February 7, 2025:
Yesterday, February 11th, the FDA informed Indivior that, following acceptance of the proposed label for SUBLOCADE, there were no outstanding items to address, but that final review of the SUBLOCADE label changes has been delayed.
Indivior will provide further updates on the status of the approval of the proposed SUBLOCADE label changes as appropriate.
SOURCE Indivior PLC
More Post from the Author
- Global Military Products Awarded Contract Exceeding $635 Million for 155mm Artillery Munitions
- SJE Acquires AMI Global, Expanding Industrial Internet of Things (IIoT) Capabilities
- Lumenuity Selected as Finalist for Pepperdine's Most Fundable Companies of 2025
- APhA alarmed by claims of harm from acetaminophen without substantive science
- Exiger Named Presenting Sponsor Of Navy 250 Gala Celebrating Navy & Marine Corps' 250th Anniversary